Literature DB >> 11517816

Lipid management: tools for getting to the goal.

J M McKenney.   

Abstract

The treatment of hypercholesterolemia in the United States begins with the recognition of elevated low-density lipoprotein cholesterol (LDL-C) as the primary target. An optimal LDL-C level has been defined as < 100 mg/dL. The first step in lowering LDL-C continues to be lifestyle modification, which includes a restriction of saturated fat and cholesterol, increased physical activity, and weight loss, if applicable. Approximately half of all patients with elevated LDL-C levels will ultimately need treatment with a lipid-lowering drug to achieve treatment goals. The preferred drug for first-line treatment in most patients is a statin; a bile acid resin or niacin can be used in patients who cannot tolerate statins or who are not candidates for stain therapy. Combination therapy is an option, with several combinations showing efficacy in lowering LDL-C (statin plus bile acid resin, niacin plus bile acid resin) and in lowering both LDL-C and triglycerides (statin plus fibrate, statin plus niacin, bile acid resin plus niacin). Successful lipid management includes treating to reach the LDL-C goal level, treating to reach the non-high-density lipoprotein cholesterol goal level if applicable, and managing other risk factors for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517816

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  7 in total

1.  Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers.

Authors:  Nicole M Iverson; Sarah M Sparks; Bahar Demirdirek; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Acta Biomater       Date:  2010-02-17       Impact factor: 8.947

2.  Dual use of amphiphilic macromolecules as cholesterol efflux triggers and inhibitors of macrophage athero-inflammation.

Authors:  Nicole M Iverson; Nicole M Plourde; Sarah M Sparks; Jinzhong Wang; Ekta N Patel; Pratik S Shah; Daniel R Lewis; Kyle R Zablocki; Gary B Nackman; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Biomaterials       Date:  2011-08-03       Impact factor: 12.479

3.  Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.

Authors:  Stéphane Bissonnette; Rafik Habib; Fotini Sampalis; Stella Boukas; John S Sampalis
Journal:  Can J Cardiol       Date:  2006-10       Impact factor: 5.223

Review 4.  Management of hypercholesterolaemia in postmenopausal women.

Authors:  Michael H Davidson; Kevin C Maki; Sherry Katz Karp; Kate A Ingram
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Managing dyslipidemia in chronic kidney disease.

Authors:  Daniel E Weiner; Mark J Sarnak
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

Review 6.  Potential cellular receptors involved in hepatitis C virus entry into cells.

Authors:  Daniel Favre; Beat Muellhaupt
Journal:  Lipids Health Dis       Date:  2005-04-19       Impact factor: 3.876

7.  Faecal bacterial and short-chain fatty acids signature in hypercholesterolemia.

Authors:  A B Granado-Serrano; M Martín-Garí; V Sánchez; M Riart Solans; R Berdún; I A Ludwig; L Rubió; E Vilaprinyó; M Portero-Otín; J C E Serrano
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.